

## Supporting information for:

# Orally bioavailable quinoxaline inhibitors of 15-prostaglandin dehydrogenase (15-PGDH) promote tissue repair and regeneration

Bin Hu,<sup>a</sup> Kosuke Toda,<sup>b</sup> Xiaoyu Wang,<sup>a</sup> Monika I. Antczak,<sup>a</sup> Julianne Smith,<sup>b</sup> Sophie Geboers,<sup>a</sup> Gen Nishikawa,<sup>b</sup> Hongyun Li,<sup>b</sup> Dawn Dawson,<sup>b</sup> Stephen Fink,<sup>b</sup> Amar B. Desai,<sup>b</sup> Noelle S. Williams,<sup>a</sup> Sanford D. Markowitz,<sup>b,c,d,\*</sup> and Joseph M. Ready<sup>a,\*</sup>

<sup>a</sup>UT Southwestern Medical Center, Department of Biochemistry, 5323 Harry Hines Blvd. Dallas, Texas, 75390-9038.


<sup>b</sup>Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. <sup>c</sup>Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, OH 44106, USA. <sup>d</sup>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.

[Joseph.ready@utsouthwestern.edu](mailto:Joseph.ready@utsouthwestern.edu)


[Sanford.markowitz@case.edu](mailto:Sanford.markowitz@case.edu)

### Contents


Supplementary Figures	S2
Supplementary Table	S4
Representative HPLC Traces	S6
NMR Spectra	S9



**Figure S1.** Elevation of PGE2 levels in colon and lung in female C57Bl/6 mice following a 10 (A) or 2.5 (B) mg/kg IP dose of the indicated compound.




**Figure S2.** A. Inhibition of 15-PGDH enzymatic activity in the mouse lung following a 20 or 40 mg/kg oral dose of **49**. B. Time course of inhibition of 15-PGDH enzyme activity in the mouse lung following IP delivery of **4** or **49**.




**Figure S3.** A. Bone marrow cellularity at day 20 (n = 8 – 10). B. Hematopoietic stem and progenitor cells (LSK positive cells) at day 20 (n = 9 – 14). \*P < 0.05, \*\*P < 0.005. C. Representative plots depicting hematopoietic stem and progenitor cell (HSPC) identification (gated plot area) among BM hematopoietic lineage negative cells by Sca1 (x-axis) and c-Kit (y-axis) staining in mice treated as indicated, 21 days post-transplantation. A-C experimental outline: Mice were irradiated at day -1 and dosing with vehicle or drug was initiated. (+)-4 was dosed in vehicle 1 (10% EtOH, 5% cremophor EL, 85% D5W, pH 7.4. 49 was dosed in vehicle 2 (10% DMSO, 25% PEG 400, 1% Tween-80, 64% D5W, pH 7.6). On day 0, 10<sup>6</sup> bone marrow cells were injected IV and drug or vehicle administration was continued twice daily.

### 2nM PGDH



**Figure S4.** IC50 values for two inhibitors of 15-PGDH (2 nM enzyme) in the presence of the indicated substrate (PGE2) concentration.




	Melting Point ( $^{\circ}\text{C}$ )		
	Enzyme	Enzyme+NADH	Enzyme+NADH+49
15-PGDH	47	50.5	71
HSD17B10	53	57	57
BDH2	32.5	56	56.5


**Figure S5: 49 binds 15-PGDH but not HSD17B10 or BDH2 as judged by melting point.** 10uM of 49, 0.25ug of human PGDH, HSD17B10 or BDH2, NADH 125uM, HSD17B10 and BDH2 were purchased from SydLabs. Data for 15-PGDH from main text.

**Table S1.** Antibodies used in the identification and quantification of hematopoietic stem and precursor cells.

Antibody	Clone	Manufacturer
CD45R/B220	RA3-6B2	BD Pharmingen
CD11b	M1/70	BD Pharmingen
CD3e	500A2	BD Pharmingen
Ly-6G and Ly-6C	RB6-8C5	BD Pharmingen
TER-119	TER-119	BD Pharmingen
Ly-6A/E (Sca-1)	D7	Invitrogen
CD117 (c-Kit)	2B8	Invitrogen





**Figure S6.** X-ray crystal structure of **49** showing 2 molecules in the unit cell. CCDC 2179639





**Figure S7.** Compound progression from initial hit to potent, stable lead **49**.

## Representative HPLC Traces (254 nM absorbance)



### Compound 9





### Compound 10





### Compound 17





### Compound 18





### Compound 20





### Compound 33





### Compound 39







### Compound 40







### Compound 49











































































PROTON\_01






















PROTON\_01







CARBON\_01
































































































PROTON\_01



CARBON\_01

